Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 14.40 | -0.16% |
| CAC 40 | 8,119.05 | 22.87 | -0.28% |
| DAX 40 | 23,975.08 | 108.45 | -0.45% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,326.74 | 5.65 | 0.05% |
| HKSE | 25,679.78 | 245.87 | -0.95% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,764.40 | 110.54 | -0.86% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,710.70 | 10.50 | -0.12% |
| SSE Composite Index | 4,078.64 | 7.71 | -0.19% |